Compare · DXCM vs IRTC
DXCM vs IRTC
Side-by-side comparison of DexCom Inc. (DXCM) and iRhythm Holdings Inc. (IRTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and IRTC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $32.10B, about 9.0x IRTC ($3.55B).
- Over the past year, DXCM is up 27.6% and IRTC is down 39.7% - DXCM leads by 67.3 points.
- DXCM has been more active in the news (6 items in the past 4 weeks vs 5 for IRTC).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- iRhythm Holdings Inc.
- Price
- $83.49-1.85%
- $105.90-1.74%
- Market cap
- $32.10B
- $3.55B
- 1M return
- -3.40%
- -5.40%
- 1Y return
- +27.60%
- -39.66%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2016
- News (4w)
- 6
- 5
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
iRhythm Holdings Inc.
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest IRTC
- Amendment: SEC Form SCHEDULE 13G/A filed by iRhythm Holdings Inc.
- iRhythm Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care
- iRhythm Provides Update on Cybersecurity Incident Previously Disclosed in June 2026
- iRhythm Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Chief Financial Officer Wilson Daniel G. sold $94,175 worth of shares (773 units at $121.83), decreasing direct ownership by 2% to 34,887 units (SEC Form 4) (tax withholding)
- iRhythm Holdings to Participate in Wells Fargo 21st Annual Healthcare Conference
- iRhythm Holdings Inc. filed SEC Form 8-K: Leadership Update
- President and CEO Blackford Quentin S. was granted 48,534 shares and sold $3,348,012 worth of shares (26,859 units at $124.65), increasing direct ownership by 11% to 226,008 units (SEC Form 4) (for withholding tax)
- CBO and CLO Murphy Patrick Michael was granted 13,589 shares and sold $884,156 worth of shares (7,093 units at $124.65), increasing direct ownership by 10% to 69,699 units (SEC Form 4) to satisfy withholding tax